Venture investors, pharmaceutical and technology companies and
academic collaborators work closely with FACIT to identify collaboration, licensing and new commercial venture opportunities.
Along with our
collaborator in this program, Ludwig Cancer Research, we
work to identify promising new drug combinations, partner with companies to gain access to these drugs, and then provide investment capital and clinical trial support to the
academic investigators to help kick - start clinical development.